Income Statement Gan & Lee Pharmaceuticals.

Equities

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 05/12/2025			5-day change	1st Jan Change
63.60 ^CNY	+1.92%		+0.90%	+44.22%

11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
10-30	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

5239a98b8f9730fdae03a2.9SVk-qkUTclrdCNC_7-B7zwixbalTm1tnNa3EtOQddw.hBw2vd9OAJooNlcpl-DI2F5Yl8zIOAE-0KX5X4H8NOjHQh2_2nUXjxNNTA

Published financial data: GAN & LEE PHARMACEUTICALS.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	3.36B	3.61B	1.71B	2.6B	3.03B
Other Revenues, Total	-	113K	2.4M	11.6M	11.4M
Total Revenues	3.36B	3.61B	1.71B	2.61B	3.05B
Cost of Goods Sold, Total	310M	400M	444M	725M	777M
Gross Profit	3.05B	3.21B	1.27B	1.88B	2.27B
Selling General & Admin Expenses, Total	1.2B	1.3B	1.33B	1.16B	1.42B
Provision for Bad Debts	-4.94M	19.38M	27.25M	15.96M	-20.15M
R&D Expenses	420M	475M	562M	501M	541M
Other Operating Expenses	20.98M	26.21M	20.95M	23.61M	29.83M
Other Operating Expenses, Total	1.64B	1.82B	1.94B	1.7B	1.97B
Operating Income	1.41B	1.39B	-676M	180M	295M
Interest Expense, Total	-	-965K	-776K	-552K	-292K
Interest And Investment Income	67.38M	322M	187M	141M	153M
Net Interest Expenses	67.38M	321M	186M	140M	153M
Currency Exchange Gains (Loss)	262K	-713K	-2.39M	2.4M	6.61M
Other Non Operating Income (Expenses)	-3.83M	-3.34M	-1.6M	-802K	-2.03M
EBT, Excl. Unusual Items	1.48B	1.71B	-494M	322M	452M
Gain (Loss) On Sale Of Investments	-42.77M	-54.45M	-80.66M	-17.92M	157M
Gain (Loss) On Sale Of Assets	330K	-1.7M	-5.18M	-494K	1.15M
Asset Writedown	-6.85M	-	-40.92M	-12.55M	-5.02M
Other Unusual Items	16.12M	44.96M	38.69M	15.01M	25.32M
EBT, Incl. Unusual Items	1.45B	1.7B	-582M	306M	630M
Income Tax Expense	215M	243M	-143M	-34.09M	15.72M
Earnings From Continuing Operations	1.23B	1.45B	-440M	340M	615M
Net Income to Company	1.23B	1.45B	-440M	340M	615M
Minority Interest	72	217	22	-163K	46
Net Income - (IS)	1.23B	1.45B	-440M	340M	615M
Net Income to Common Incl Extra Items	1.23B	1.45B	-440M	340M	615M
Net Income to Common Excl. Extra Items	1.23B	1.45B	-440M	340M	615M
Per Share Items
Net EPS - Basic	2.31	2.59	-0.78	0.6	1.04
Basic EPS - Continuing Operations	2.31	2.59	-0.78	0.6	1.04
Basic Weighted Average Shares Outstanding	533M	561M	563M	567M	591M
Net EPS - Diluted	2.31	2.59	-0.78	0.6	1.04
Diluted EPS - Continuing Operations	2.31	2.59	-0.78	0.6	1.04
Diluted Weighted Average Shares Outstanding	533M	561M	563M	567M	591M
Normalized Basic EPS	1.73	1.9	-0.55	0.35	0.48
Normalized Diluted EPS	1.73	1.9	-0.55	0.35	0.48
Dividend Per Share	0.4	0.3	-	0.2	1.5
Payout Ratio	16.3	15.46	-38.33	-	68.42
Supplemental Items
EBITDA	1.57B	1.57B	-486M	395M	546M
EBITA	1.42B	1.4B	-666M	190M	305M
EBIT	1.41B	1.39B	-676M	180M	295M
EBITDAR	1.58B	1.57B	-480M	402M	554M
Total Revenues (As Reported)	3.36B	3.61B	1.71B	2.61B	3.05B
Effective Tax Rate - (Ratio)	14.86	14.34	24.54	-11.14	2.49
Total Current Taxes	224M	255M	639K	-9.81M	44.29M
Total Deferred Taxes	-9.06M	-11.51M	-144M	-24.28M	-28.57M
Normalized Net Income	924M	1.07B	-309M	201M	283M
Interest Capitalized	-	-	-	-	-
Interest on Long-Term Debt	-	-	-	552K	292K
Non-Cash Pension Expense	6.89M	813K	1.87M	3.07M	7.13M
Supplemental Operating Expense Items
Advertising Expense	-	-	-	-	-
Marketing Expenses	686M	686M	695M	482M	590M
Selling and Marketing Expenses	915M	1B	1.09B	946M	1.17B
General and Administrative Expenses	286M	299M	247M	217M	256M
Research And Development Expense From Footnotes	420M	475M	562M	501M	541M
Net Rental Expense, Total	4.26M	5.47M	5.58M	7.72M	8.76M
Imputed Operating Lease Interest Expense	-	-	2.22M	3.15M	3.34M
Imputed Operating Lease Depreciation	-	-	3.36M	4.57M	5.42M
Stock-Based Comp., R&D Exp. (Total)	-	-	-	21.39M	28.01M
Stock-Based Comp., S&M Exp. (Total)	-	-	-	2.54M	15.97M
Stock-Based Comp., G&A Exp. (Total)	-	-	-	19.87M	50.8M
Stock-Based Comp., Other (Total)	-	2.53M	19.59M	6.31M	18.08M
Total Stock-Based Compensation	-	2.53M	19.59M	50.11M	113M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	2.82B	3.31B	2.89B	2.44B	903M
Short Term Investments	945M	276M	201M	-	-
Trading Asset Securities, Total	787M	1.62B	1.64B	2.41B	1.5B
Total Cash And Short Term Investments	4.56B	5.21B	4.73B	4.85B	2.4B
Accounts Receivable, Total	827M	935M	190M	385M	214M
Other Receivables	5M	160K	986K	-	31.89M
Total Receivables	832M	935M	191M	385M	246M
Inventory	493M	651M	649M	861M	1.05B
Other Current Assets, Total	76.58M	77.95M	97.36M	76.73M	89.07M
Total Current Assets	5.96B	6.87B	5.66B	6.18B	3.79B
Gross Property Plant And Equipment	2.59B	3.2B	4.38B	4.86B	5.01B
Accumulated Depreciation	-445M	-609M	-723M	-979M	-1.13B
Net Property Plant And Equipment	2.15B	2.6B	3.66B	3.89B	3.88B
Long-term Investments	466M	231M	-	335M	497M
Other Intangibles, Total	239M	296M	293M	278M	273M
Deferred Tax Assets Long-Term	14.93M	30.8M	138M	169M	207M
Deferred Charges Long-Term	544M	589M	743M	822M	925M
Other Long-Term Assets, Total	135M	240M	107M	49.99M	2.47B
Total Assets	9.51B	10.85B	10.61B	11.72B	12.04B
Liabilities
Accounts Payable, Total	14.79M	26.15M	41.46M	94.82M	116M
Accrued Expenses, Total	121M	174M	190M	193M	183M
Current Portion of Leases	-	5.07M	5.69M	2.18M	1.33M
Current Income Taxes Payable	53.35M	106M	1.35M	1.42M	1.49M
Unearned Revenue Current, Total	68.44M	36.56M	68.13M	52.99M	63.25M
Other Current Liabilities	152M	138M	506M	429M	436M
Total Current Liabilities	410M	486M	813M	773M	801M
Long-Term Leases	-	12.17M	8.33M	5.45M	3.31M
Unearned Revenue Non Current	126M	142M	188M	180M	169M
Deferred Tax Liability Non Current	31.78M	36.15M	-	-	12.11M
Other Non Current Liabilities	1.69M	10.2M	12.27M	14M	2.97M
Total Liabilities	569M	686M	1.02B	973M	988M
Common Stock, Total	562M	562M	566M	594M	601M
Additional Paid In Capital	2.47B	2.48B	2.56B	3.35B	3.59B
Retained Earnings	5.9B	7.13B	6.53B	6.87B	7.06B
Treasury Stock	-	-	-71.36M	-71.36M	-201M
Comprehensive Income and Other	-1.55M	-3.44M	3.44M	3.82M	4.04M
Total Common Equity	8.94B	10.17B	9.59B	10.74B	11.05B
Minority Interest	-162K	-162K	-163K	404	-
Total Equity	8.94B	10.17B	9.59B	10.74B	11.05B
Total Liabilities And Equity	9.51B	10.85B	10.61B	11.72B	12.04B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	562M	562M	562M	590M	599M
ECS Total Common Shares Outstanding	562M	562M	562M	590M	599M
Book Value / Share	15.92	18.11	17.07	18.21	18.46
Tangible Book Value	8.7B	9.87B	9.29B	10.46B	10.78B
Tangible Book Value Per Share	15.49	17.58	16.55	17.73	18
Total Debt	0	17.24M	14.01M	7.62M	4.64M
Net Debt	-4.56B	-5.19B	-4.71B	-4.85B	-2.4B
Debt Equivalent Oper. Leases	34.09M	43.73M	44.6M	61.79M	70.08M
Minority Interest, Total (Incl. Fin. Div)	-162K	-162K	-163K	404	-
Account Code - Inventory Valuation	6	6	3	3	3
Inventories - Raw Materials, Total	130M	240M	232M	316M	327M
Inventories - Work In Process, Total	329M	358M	317M	445M	526M
Inventories - Finished Goods, Total	37.52M	54.17M	128M	114M	182M
Inventories - Others	272K	2.87M	11.38M	15.38M	28.28M
Buildings, Total	1.01B	1.05B	1.14B	1.37B	2.14B
Machinery, Total	1.17B	1.26B	1.22B	1.47B	1.6B
Full Time Employees	2.93K	3.28K	4.06K	4.48K	5.24K
Accumulated Allowance for Doubtful Accounts (Supple)	89.99K	19.36M	46.29M	44.55M	1.73M

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	1.23B	1.45B	-440M	340M	615M
Depreciation & Amortization - CF	152M	173M	185M	209M	242M
Amortization of Goodwill and Intangible Assets - (CF)	5.39M	9.1M	10.21M	10.16M	10.04M
Depreciation & Amortization, Total	158M	182M	195M	219M	252M
Amortization of Deferred Charges, Total - (CF)	3.62M	4.72M	6.81M	7.99M	6.8M
(Gain) Loss From Sale Of Asset	-330K	1K	-486K	17.58M	-158M
(Gain) Loss on Sale of Investments - (CF)	-20.47M	-85.63M	-6.91M	-63.33M	-61.25M
Asset Writedown & Restructuring Costs	6.85M	1.69M	46.58M	13.38M	5.73M
Provision and Write-off of Bad Debts	-4.94M	19.38M	27.25M	15.96M	-20.15M
Other Operating Activities, Total	2.9M	-141M	-50.7M	-43.57M	-78.34M
Change In Accounts Receivable	-8.71M	-155M	2.22B	481M	132M
Change In Inventories	-25.3M	-158M	-35.44M	-239M	-203M
Change In Accounts Payable	-91.71M	-30.39M	-1.55B	-665M	-37.49M
Change In Deferred Taxes	-9.06M	-11.51M	-144M	-24.28M	-28.57M
Change in Other Net Operating Assets	-	-	19.59M	50.11M	113M
Cash from Operations	1.24B	1.08B	297M	109M	537M
Capital Expenditure	-582M	-692M	-983M	-553M	-441M
Sale of Property, Plant, and Equipment	856K	1.02M	60.42K	356K	-
Divestitures	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-2.66B	56.66M	328M	-744M	87.94M
Other Investing Activities, Total	19.33M	136M	213M	320M	90.83M
Cash from Investing	-3.22B	-498M	-442M	-977M	-262M
Long-Term Debt Repaid, Total	-	-	-	-	-1.99M
Total Debt Repaid	-	-	-	-	-1.99M
Issuance of Common Stock	2.55B	-	71.36M	760M	139M
Repurchase of Common Stock	-	-	-	-	-17.49M
Common Dividends Paid	-201M	-225M	-168M	-	-421M
Common & Preferred Stock Dividends Paid	-201M	-225M	-168M	-	-421M
Other Financing Activities, Total	-104M	-4.32M	-3.77M	-5.03M	-
Cash from Financing	2.24B	-229M	-101M	755M	-301M
Foreign Exchange Rate Adjustments	-881K	-2.68M	4.19M	2.36M	-951K
Net Change in Cash	258M	348M	-242M	-111M	-26.38M
Supplemental Items
Cash Interest Paid	-	-	-	-	-
Cash Income Tax Paid (Refund)	439M	324M	116M	-5M	100M
Levered Free Cash Flow	380M	174M	-130M	-586M	78.76M
Unlevered Free Cash Flow	380M	175M	-130M	-586M	78.94M
Change In Net Working Capital	83.79M	191M	-1.05B	422M	36.44M
Net Debt Issued / Repaid	-	-	-	-	-1.99M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	11.38	8.54	-3.94	1.01	1.55
Return on Total Capital	12.27	9.09	-4.27	1.11	1.69
Return On Equity %	17.08	15.21	-4.45	3.35	5.64
Return on Common Equity	17.08	15.21	-4.45	3.35	5.64
Margin Analysis
Gross Profit Margin %	90.78	88.93	74.07	72.21	74.48
SG&A Margin	35.73	36.04	77.9	44.58	46.72
EBITDA Margin %	46.78	43.41	-28.35	15.13	17.91
EBITA Margin %	42.24	38.74	-38.9	7.29	10
EBIT Margin %	42.08	38.49	-39.5	6.9	9.67
Income From Continuing Operations Margin %	36.61	40.22	-25.67	13.05	20.18
Net Income Margin %	36.61	40.22	-25.67	13.04	20.18
Net Avail. For Common Margin %	36.61	40.22	-25.67	13.04	20.18
Normalized Net Income Margin	27.49	29.54	-18.05	7.71	9.28
Levered Free Cash Flow Margin	11.29	4.82	-7.62	-22.46	2.59
Unlevered Free Cash Flow Margin	11.29	4.84	-7.59	-22.45	2.59
Asset Turnover
Asset Turnover	0.43	0.35	0.16	0.23	0.26
Fixed Assets Turnover	1.66	1.52	0.55	0.69	0.78
Receivables Turnover (Average Receivables)	4.01	4.1	3.04	9.03	10.16
Inventory Turnover (Average Inventory)	0.64	0.7	0.68	0.96	0.81
Short Term Liquidity
Current Ratio	14.54	14.15	6.97	7.98	4.73
Quick Ratio	13.15	12.65	6.05	6.77	3.31
Operating Cash Flow to Current Liabilities	3.03	2.22	0.36	0.14	0.67
Days Sales Outstanding (Average Receivables)	91.17	89.03	119.99	40.41	36.04
Days Outstanding Inventory (Average Inventory)	569.89	522.46	534.42	380.04	450.57
Average Days Payable Outstanding	18.69	13.4	27.96	25.59	39.72
Cash Conversion Cycle (Average Days)	642.37	598.09	626.45	394.86	446.88
Long Term Solvency
Total Debt/Equity	-	0.17	0.15	0.07	0.04
Total Debt / Total Capital	-	0.17	0.15	0.07	0.04
LT Debt/Equity	-	0.12	0.09	0.05	0.03
Long-Term Debt / Total Capital	-	0.12	0.09	0.05	0.03
Total Liabilities / Total Assets	5.99	6.32	9.63	8.3	8.21
EBIT / Interest Expense	-	1.44K	-871.47	326.33	1.01K
EBITDA / Interest Expense	-	1.63K	-619.79	723.35	1.87K
(EBITDA - Capex) / Interest Expense	-	912.23	-1.89K	-279.11	363.85
Total Debt / EBITDA	-	0.01	-0.03	0.02	0.01
Net Debt / EBITDA	-2.9	-3.3	9.8	-12.14	-4.39
Total Debt / (EBITDA - Capex)	-	0.02	-0.01	-0.05	0.04
Net Debt / (EBITDA - Capex)	-4.6	-5.9	3.22	31.47	-22.59
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	16.12	7.44	-52.6	52.31	16.77
Gross Profit, 1 Yr. Growth %	14.86	5.25	-60.51	48.49	20.44
EBITDA, 1 Yr. Growth %	8.83	-0.41	-130.91	-182.22	36.12
EBITA, 1 Yr. Growth %	6.44	-1.6	-147.5	-128.8	55.09
EBIT, 1 Yr. Growth %	6.45	-1.74	-148.64	-126.65	63.62
Earnings From Cont. Operations, 1 Yr. Growth %	5.43	18.04	-130.25	-177.41	80.66
Net Income, 1 Yr. Growth %	5.43	18.04	-130.25	-177.37	80.75
Normalized Net Income, 1 Yr. Growth %	8.11	15.46	-128.96	-165.17	40.55
Diluted EPS Before Extra, 1 Yr. Growth %	0	12.12	-130.12	-176.92	73.33
Accounts Receivable, 1 Yr. Growth %	-2.38	12.97	-79.72	103.29	-44.31
Inventory, 1 Yr. Growth %	4.7	31.99	-0.41	32.66	22.36
Net Property, Plant and Equip., 1 Yr. Growth %	13.69	20.77	41.07	6.13	-0.09
Total Assets, 1 Yr. Growth %	57.76	14.15	-2.27	10.45	2.8
Tangible Book Value, 1 Yr. Growth %	62.94	13.47	-5.87	12.61	3.03
Common Equity, 1 Yr. Growth %	63.38	13.75	-5.72	12.07	2.9
Cash From Operations, 1 Yr. Growth %	7.23	-13.14	-72.48	-63.11	390.91
Capital Expenditures, 1 Yr. Growth %	43.16	18.89	42.1	-43.76	-20.3
Levered Free Cash Flow, 1 Yr. Growth %	-30.23	-54.13	-176	291.38	-112.38
Unlevered Free Cash Flow, 1 Yr. Growth %	-30.23	-53.97	-175.45	292.42	-112.42
Dividend Per Share, 1 Yr. Growth %	12.01	-25	-	-	650
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	18.67	11.7	-28.63	-15.03	33.36
Gross Profit, 2 Yr. CAGR %	17.78	9.95	-35.54	-23.43	33.73
EBITDA, 2 Yr. CAGR %	15.56	4.17	-44.47	-49.88	6.63
EBITA, 2 Yr. CAGR %	14.08	2.41	-31.56	-63.17	-32.09
EBIT, 2 Yr. CAGR %	14.05	2.27	-30.86	-64.01	-33.97
Earnings From Cont. Operations, 2 Yr. CAGR %	14.79	11.56	-40.24	-51.61	18.26
Net Income, 2 Yr. CAGR %	14.79	11.56	-40.24	-51.62	18.26
Normalized Net Income, 2 Yr. CAGR %	15.39	11.72	-42.18	-56.58	-4.29
Diluted EPS Before Extra, 2 Yr. CAGR %	11.74	5.89	-41.89	-51.87	15.47
Accounts Receivable, 2 Yr. CAGR %	0.05	5.01	-52.13	-35.79	6.18
Inventory, 2 Yr. CAGR %	12.61	17.55	14.65	14.94	27.41
Net Property, Plant and Equip., 2 Yr. CAGR %	14.57	17.17	30.53	22.36	2.97
Total Assets, 2 Yr. CAGR %	42.3	34.2	5.62	3.89	6.55
Tangible Book Value, 2 Yr. CAGR %	45.06	35.97	3.35	2.96	7.71
Common Equity, 2 Yr. CAGR %	44.67	36.32	3.56	2.79	7.39
Cash From Operations, 2 Yr. CAGR %	72.32	-3.49	-51.11	-68.14	34.58
Capital Expenditures, 2 Yr. CAGR %	6.48	30.46	29.98	-10.61	-33.05
Levered Free Cash Flow, 2 Yr. CAGR %	18.07	-43.42	-41.39	84.74	-27.46
Unlevered Free Cash Flow, 2 Yr. CAGR %	18.07	-43.33	-41.5	84.36	-27.26
Dividend Per Share, 2 Yr. CAGR %	-	-8.34	-	-18.35	-
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	12.35	14.8	-16.06	-8.12	-5.53
Gross Profit, 3 Yr. CAGR %	12.15	13.44	-21.85	-14.86	-10.95
EBITDA, 3 Yr. CAGR %	6.57	10.01	-30.48	-36.95	-29.71
EBITA, 3 Yr. CAGR %	4.24	8.64	-20.67	-48.86	-39.89
EBIT, 3 Yr. CAGR %	4.23	8.52	-20.17	-49.7	-40.38
Earnings From Cont. Operations, 3 Yr. CAGR %	4.45	15.87	-27.79	-34.86	-24.93
Net Income, 3 Yr. CAGR %	4.45	15.87	-27.79	-34.87	-24.93
Normalized Net Income, 3 Yr. CAGR %	5.49	15.42	-28.77	-39.85	-35.77
Diluted EPS Before Extra, 3 Yr. CAGR %	2.65	11.87	-30.36	-36.2	-26.22
Accounts Receivable, 3 Yr. CAGR %	20.17	4.18	-39.3	-22.48	-38.85
Inventory, 3 Yr. CAGR %	32.46	18.73	11.23	20.36	17.36
Net Property, Plant and Equip., 3 Yr. CAGR %	15.59	16.6	24.65	21.83	14.36
Total Assets, 3 Yr. CAGR %	36.44	32.22	20.74	7.21	3.53
Tangible Book Value, 3 Yr. CAGR %	39.6	33.65	20.29	6.35	2.98
Common Equity, 3 Yr. CAGR %	38.9	33.53	20.56	6.32	2.83
Cash From Operations, 3 Yr. CAGR %	9.34	37.14	-36.48	-55.49	-20.72
Capital Expenditures, 3 Yr. CAGR %	10.54	10.46	34.23	-1.69	-13.96
Levered Free Cash Flow, 3 Yr. CAGR %	7.97	-13.84	-37.88	15.54	-22.87
Unlevered Free Cash Flow, 3 Yr. CAGR %	7.88	-13.74	-37.96	15.52	-22.91
Dividend Per Share, 3 Yr. CAGR %	-	-	-	-20.63	71
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	22.48	15.31	-6.3	1.78	1.02
Gross Profit, 5 Yr. CAGR %	22.41	14.88	-10.13	-3.06	-3.12
EBITDA, 5 Yr. CAGR %	24.69	12.04	-17.87	-19.64	-17.7
EBITA, 5 Yr. CAGR %	22.26	9.52	-11.89	-29.49	-25.58
EBIT, 5 Yr. CAGR %	22.31	9.37	-11.56	-30.21	-26.02
Earnings From Cont. Operations, 5 Yr. CAGR %	22.43	13.55	-16.46	-18.29	-12.04
Net Income, 5 Yr. CAGR %	22.43	13.55	-16.46	-18.3	-12.04
Normalized Net Income, 5 Yr. CAGR %	23.14	13.66	-17.06	-21.94	-19.85
Diluted EPS Before Extra, 5 Yr. CAGR %	19.27	11.33	-18.25	-20.16	-14.75
Accounts Receivable, 5 Yr. CAGR %	27.61	19.72	-16.85	-14.15	-24.08
Inventory, 5 Yr. CAGR %	31.99	34.87	25.03	17.2	17.44
Net Property, Plant and Equip., 5 Yr. CAGR %	22.38	21.71	21.35	18.87	15.48
Total Assets, 5 Yr. CAGR %	39.32	33.04	23.16	20.07	14.85
Tangible Book Value, 5 Yr. CAGR %	45.34	36.08	23.78	20.41	15.09
Common Equity, 5 Yr. CAGR %	43.17	35.14	23.51	20.26	15.11
Cash From Operations, 5 Yr. CAGR %	19.83	9.46	-20.76	-23.51	-14.23
Capital Expenditures, 5 Yr. CAGR %	9.58	21.77	17.94	1.5	1.63
Levered Free Cash Flow, 5 Yr. CAGR %	104.23	-3.62	-15.43	16.55	-32.07
Unlevered Free Cash Flow, 5 Yr. CAGR %	104.4	-3.55	-15.54	16.54	-32.03
Dividend Per Share, 5 Yr. CAGR %	-	-	-	-	33.25